Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 3:30 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 8,612 matching trials from the live ClinicalTrials.gov search.

Filters: Indianapolis, Indiana Clear all

Conditions: Fibromyalgia, Myofascial Pain Syndrome, Muscular Diseases, Musculoskeletal Disease, Rheumatic Diseases
Interventions: Fibromyalgia Integrative Training for Teens, Cognitive Behavioral Therapy, Graded Aerobic Exercise; Behavioral
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 12 Years to 18 Years
Enrollment: 389 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 6
States / cities: Hartford, Connecticut • Indianapolis, Indiana • Boston, Massachusetts + 3 more

Conditions: Breast Cancer
Interventions: Raloxifene, Tamoxifen; Drug
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 35 Years and older · Female only
Enrollment: 19,747 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2012
U.S. locations: 492
States / cities: Huntsville, Alabama • Mobile, Alabama • Anchorage, Alaska + 369 more

Conditions: Cystic Fibrosis
Interventions: ELX/TEZ/IVA, IVA; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 458 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 46
States / cities: Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 42 more

Conditions: Breast Cancer, Cognitive Change, Cognitive Impairment, Quality of Life
Interventions: Sweep Seeker, Bird Safari, Jewel Diver, Master Gardener, Road Tour, Computerized Crossword Puzzles; Behavioral
Lead sponsor: Ohio State University; Other
Eligibility: 21 Years and older · Female only
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Advanced Solid Tumor, PIK3CA Mutation, PTEN Loss of Function Mutation
Interventions: Serabelisib, Insulin Suppressing Diet, Nab paclitaxel; Drug · Other
Lead sponsor: Faeth Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 17
States / cities: Birmingham, Alabama • Anaheim, California • Los Angeles, California + 14 more

Conditions: Venous Thromboembolism
Interventions: Rivaroxaban (Xarelto, BAY59-7939), Standard of Care; Drug
Lead sponsor: Bayer; Industry
Eligibility: Up to 17 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 23
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 19 more

Conditions: Diabetes Mellitus, Chronic Obstructive Pulmonary Disease
Interventions: Subcutaneous Insulin, Inhaled Insulin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 30 Years to 77 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 77
States / cities: Glendale, Arizona • Peoria, Arizona • Phoenix, Arizona + 59 more

Conditions: Von Willebrand Disease
Interventions: von Willebrand factor (Recombinant), Antihemophilic Factor (Recombinant); Biological
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 8
States / cities: Loveland, Colorado • Gainesville, Florida • Jacksonville, Florida + 5 more

Conditions: AML
Interventions: Quizartinib, Salvage Chemotherapy; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 367 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 36
States / cities: Duarte, California • Los Angeles, California • Sacramento, California + 31 more

Conditions: Keratoconus, Unstable, Ectasia Corneal, Bacterial Keratitis
Interventions: PXL 330 Platinum device/Riboflavin; Combination Product
Lead sponsor: Eye Specialists of Indiana; Other
Eligibility: 12 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Atopic Dermatitis, Atopic, Dermatitis, AD, Eczema
Interventions: ATI-045, Placebo; Drug
Lead sponsor: Aclaris Therapeutics, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 53
States / cities: Phoenix, Arizona • Tucson, Arizona • Bryant, Arkansas + 47 more

Conditions: Atopic Dermatitis
Interventions: Upadacitinib (ABT-494); Drug
Lead sponsor: AbbVie; Industry
Eligibility: 2 Years to 12 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 15
States / cities: Huntington Beach, California • Los Angeles, California • Coral Gables, Florida + 12 more

Conditions: Persistent Allergic Asthma
Interventions: Omalizumab, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 271 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 50
States / cities: Jasper, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 46 more

Conditions: High Grade Osteosarcoma, Localized Osteosarcoma, Metastatic Osteosarcoma, Secondary Osteosarcoma
Interventions: Bone Scan, Cabozantinib S-malate, Cisplatin, Computed Tomography, Doxorubicin Hydrochloride, Magnetic Resonance Imaging, Methotrexate, Surgical Procedure, X-Ray Imaging; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 40 Years
Enrollment: 1,122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 181
States / cities: Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 134 more

Conditions: Hepatitis C Virus Infection
Interventions: VOX, SOF/VEL, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 31
States / cities: Los Angeles, California • Palo Alto, California • Pasadena, California + 26 more

Conditions: Metastatic Dedifferentiated Liposarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Unresectable Dedifferentiated Liposarcoma, Unresectable Undifferentiated Pleomorphic Sarcoma
Interventions: Biospecimen Collection, Diagnostic Imaging Testing, Doxorubicin, Echocardiography Test, Multigated Acquisition Scan, Pembrolizumab; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 365 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 258
States / cities: Phoenix, Arizona • Tucson, Arizona • Dublin, California + 209 more

Conditions: Dyslipidemia
Interventions: Evolocumab, Placebo; Biological · Drug
Lead sponsor: Amgen; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 27,564 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 326
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 275 more

Conditions: Primary Sclerosing Cholangitis, Compensated Cirrhosis
Interventions: Cilofexor; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 16
States / cities: Chandler, Arizona • Pasadena, California • San Francisco, California + 11 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Exenatide Once Weekly, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 14,752 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 139
States / cities: Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 124 more

Conditions: Metastatic Melanoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Hodgkin Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Melanoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Rhabdomyosarcoma, Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Refractory Hodgkin Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Melanoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Rhabdomyosarcoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma
Interventions: Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Pharmacological Study; Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Months to 30 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 24
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 21 more

Conditions: Kidney Cancer
Interventions: Interleukin-2; Drug
Lead sponsor: Loyola University; Other
Eligibility: 16 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2002
U.S. locations: 15
States / cities: Duarte, California • Los Angeles, California • Oakland, California + 11 more

Conditions: Toxoplasmosis, Cerebral, HIV Infections
Interventions: Pyrimethamine, Leucovorin calcium; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1994
U.S. locations: 24
States / cities: Palo Alto, California • Torrance, California • Miami, Florida + 16 more

Conditions: Plaque, Gingivitis
Interventions: 2 mg KSL-W, 4 mg KSL-W, 6 mg KSL-W, 10 mg KSL-W, 20 mg KSL-W, 30 mg KSL-W, 50 mg KSL-W, 75 mg KSL-W, 100 mg KSL-W, Placebo; Drug · Other
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 64 Years
Enrollment: 135 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Pancreatic Adenocarcinoma
Interventions: Gemzar (Gemcitabine), TH-302; Drug
Lead sponsor: ImmunoGenesis; Industry
Eligibility: 18 Years and older
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 59
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 52 more

Search by objective public record fields.

Fibromyalgia Integrative Training for Adolescents With Juvenile Fibromyalgia

Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women

A Study Evaluating the Long-term Safety of VX-445 Combination Therapy

Computerized Cognitive Training in Breast Cancer Survivors

Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations

EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis

A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With COPD

rVWF IN PROPHYLAXIS

(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive

Safety and Effectiveness of the PXL Platinum 330 System for Corneal Collagen Cross-Linking in Eyes With Corneal Thinning Position

ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Participants With Severe Atopic Dermatitis

Evaluate the Effect of Omalizumab on Markers of Asthma Impairment in Patients With Persistent Allergic Asthma

A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Genotype 1 HCV Infection

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas

Interleukin-2 in Treating Patients With Stage III or Stage IV Kidney Cancer

Primary Prophylaxis of Cerebral Toxoplasmosis in HIV-Infected Patients

Safety and Tolerability of Antiplaque Chewing Gum in a Gingivitis Population

Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma